Skip to main content

Table 3 Frequency of anti-malarials used by hospitalized patients, Uganda, 2014

From: Quality of care for adult in-patients with malaria in a tertiary hospital in Uganda

Anti-malarial

Number

n, %

Patient-level

 Pre-admission, n = 97

  Artemether-Lumefantrine only

50

52

  Quinine only

22

23

  Sulfadoxine-Pyrimethamine only

9

9

  Artesunate only

5

5

  Coartem + Quinine only

4

4

  Duocotecxin only

2

2

  Artemether only

1

1

  Artesunate + Duocotexcin only

1

1

  P-alaxin + Quinine only

1

1

  Artemether + Quinine + Doxycycline only

1

1

  Dihydroartemisinin-Piperaquine only

1

1

 In-hospital, n = 100*

  Artesunate only±

47

47

  Quinine only~

23

23

  Artemether-Lumefantrine only

15

15

  Artesunate + Artemether-Lumefantrine only

  

  Quinine + Artemether/Lumefantrine only

3

3

  Sulfadoxine-Pyrimethamine only

2

2

  Artesunate + Quinine only

2

2

Drug-level

 Pre-admission, n = 105

  Artemether-Lumefantrine

54

51

  Quinine

28

27

  Sulfadoxine-Pyrimethamine

9

9

  Artesunate

6

6

  Duocotexcin

3

3

  Artemether

2

2

  Dihydroartemisinin-Piperaquine

2

2

  Doxycycline

1

1

 In-hospital, n = 113

  Artesunate

57

50

  Quinine

28

25

  Artemether-Lumefantrine

26

23

  Sulfadoxine-Pyrimethamine

2

2

  1. *Only 13% (11/83) of in-patients who received injectable artesunate or quinine received follow-up oral artemether-lumefantrine; ±68% (32/47) of the in-patients presented with both admission and discharge malaria diagnoses [median length of hospital stay: 4 (IQR, 3 to 5) days]; ~91% (21/23) of the in-patients had both admission and discharge malaria diagnoses [median length of hospital stay: 3 (IQR, 2 to 4) days]
Back to article page

Malaria Journal

ISSN: 1475-2875

Contact us